by Matthew Johnson | Oct 9, 2026 | Claim Construction, District Court, PTAB News, Trial Institution
By Ash Hashmi,* Cameron Hart, Ashvi Patel, and Matt Johnson – The USPTO designated as informative three recent Director decisions denying institution of IPR in response to inconsistent claim construction by petitioners in parallel litigation before the PTAB and...
by Matthew Johnson | Mar 26, 2026 | Claim Construction, PTAB News, PTAB Trial Basics, Trial Institution
By Laura Vining and Matt Johnson – USPTO Director John Squires issued a decision on November 5, 2025, vacating a prior institution decision and denying institution in Tesla, Inc. v. Intellectual Ventures II LLC, IPR2025-00340, Paper 18. Director Squires denied...
by Matthew Johnson | Mar 1, 2026 | Claim Construction, Trial Institution
By Hannah Mehrle and Matt Johnson – In two related cases involving Generac Power Systems, Inc. as Petitioner and Champion Power Equipment, Inc. as Patent Owner, Director Squires initiated sua sponte Director Review of the Board’s Decisions to grant institution...
by Matthew Johnson | Feb 4, 2026 | Claim Construction, PTAB News, PTAB Trial Basics, Trial Institution
By Ian Adams, Matt Modderman, Matt Johnson – USPTO Director John Squires issued a decision on October 3, 2025, denying a request to discretionarily deny institution in Caption Health, Inc. v. The University of British Columbia, IPR2025-01422, Paper 15 at 3 (Dec....
by Matthew Johnson | Nov 19, 2025 | Claim Construction
By Thane Bonnett* and Matt Johnson – In its recent decision in RØDE Microphones, LLC et. al. vs. Zaxcom, Inc., the PTAB declined to apply collateral estoppel based on prior post-grant proceedings because the prior proceedings had applied a different standard of...
by Matthew Johnson | Oct 29, 2025 | Claim Construction, PTAB News, PTAB Trial Basics, Trial Institution
By Evan Tassis and Matt Johnson – In a recent decision, Acting Director Coke Morgan Stewart granted Patent Owner’s request for discretionary denial in Sun Pharmaceuticals Industries Inc. v. Nivagen Pharmaceuticals, Inc., IPR2025-00893. While some factors...
